팝업레이어 알림

팝업레이어 알림이 없습니다.


Innovation for

Global Leader
of Network

Clinical & non-clinical
pipeline with

  • Notice

      2023-04-27 SK증권 큐리언트 분석 리포트
      2023-03-20 2023년 큐리언트의 국문 및 영문 IR자료
      2023-01-05 IBK투자증권 큐리언트 분석 리포트
      2022-12-01 신한투자증권 큐리언트 분석 리포트
      2022-08-22 큐리언트 텔레그램 채널 오픈 안내
  • Press Release

      2023-04-28 큐리언트 "Q702, 국제학회서 희귀혈액암 치료 대안으로 소개"
      2023-04-20 큐리언트 "Q901, '합성된 합성치사' 항암 기전 추가 확인"
      2023-04-18 큐리언트 "면역항암제 'Q702', 1상서 항암면역 활성화 입증"
      2023-04-03 큐리언트, 항암치료제 Q901 국내 임상 1/2상 임상시험계획 승인 신청
      2023-03-16 큐리언트, CDK7 표적 항암제 적응증 확장 연구 결과 발표
  • Company

    Founded in 2008, Qurient takes a pioneering position in the newly emerging biotech industry in Korea. Qurient introduced a unique virtual biotech model, running R&D operations not only in clinical development phases, but also in early discovery research stage, named ‘Network R&D’ model.See More

  • Business philosophy

    Innovation for unmet medical needs

    Qurient’s mission is to provide innovation for unmet medical needs to help patients around the world. Through fulfilling the mission, Qurient will be able to create concrete value for its shareholders. See More

  • Pipeline

    Qurient portfolio plan aims to achieve balanced innovation by strategic positioning of the R&D programs.See More

  • IR/PR

    Dear Qurient shareholders

    Qurient would like to share brief updates on current progress made on its portfolio programs. See More

information for download file